SCHEMBL8244458

SCHEMBL8244458

NCC(N)c1cccc(F)c1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
TAAR1 Q96RJ0 2/20 0.44
AOC3 Q16853 1/20 0.44
GBA1 P04062 1/20 0.43
HDAC4 P56524 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
SLC7A5 Q01650 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9902786 1.00 IDO1 (0.46) IDO1TDO2SLC6A2SLC6A4TAAR1
Hydrochloric Acid SCHEMBL3722983 0.98 IDO1 (0.49) IDO1TDO2SLC6A2SLC6A4TAAR1
SCHEMBL11084543 0.86 TAAR1 (0.47) IDO1TDO2SLC6A2SLC6A4TAAR1
SCHEMBL3542231 0.84 TAAR1 (0.46) TAAR1
SCHEMBL31211651 0.83 IDO1 (0.46) IDO1TDO2SLC6A2SLC6A4TAAR1
SCHEMBL27787892 0.83 IDO1 (0.46) IDO1TDO2SLC6A2SLC6A4TAAR1
SCHEMBL432890 0.82 HDAC4 (0.44) IDO1TDO2SLC6A2SLC6A4AOC3
SCHEMBL1730007 0.82 AOC3 (0.46) IDO1TDO2SLC6A2SLC6A4AOC3
SCHEMBL1464027 0.82 HDAC4 (0.44) IDO1TDO2SLC6A2SLC6A4AOC3
SCHEMBL1730261 0.82 AOC3 (0.46) IDO1TDO2SLC6A2SLC6A4AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP claimed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US claimed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US claimed
EP-2462141-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 EP claimed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
WO-2007076423-A2 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 WO disclosed
US-4129661-A 4,5-Dihydro-2-lower alkoxycarbonylamino-4-phenylimidazoles and substituted phenyl derivatives thereof SYNTEX (U.S.A.) INC. (US) 1978-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC IDO1 4057/4885TDO2 4776/4885SLC6A2 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.